Compare Enveric Biosciences Inc (ENVB) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Skyworks Solutions Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Skyworks Solutions Inc trades at $76.35 (market cap $12.15B). The key difference: Skyworks Solutions Inc is far larger — about 1786.8× Enveric Biosciences Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Skyworks Solutions Inc for 50 Days on average.
| ENVB | SWKS | |
|---|---|---|
Market Cap | $6.80M | $12.15B |
Volume | 64,867 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $10.80 | $91.45 |
52-Week Low | $1.27 | $52.50 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | -$1.49M | $12.03B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
Skyworks Solutions (SWKS) trades at $80.75, down 3.21% today, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.1M. Key developments include the pending Qorvo merger, which has driven recent volatility and analyst optimism about potential synergies.
The investment outlook is mixed: strong analyst support (60% buy ratings) and merger potential offer upside, but declining fundamentals and bearish technicals present near-term risks. The consensus price target of $78.80 suggests limited upside from current levels, making careful monitoring of merger progress and Q3 earnings crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
